A Phase 2 interventional study of Olaparib and Pembrolizumab in Recurrent Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine — 6 open to participants now, 12 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Washington University School of Medicine.
Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 in phase 2, reaches primary completion later than 1 of the 11 other live ones, and was the 15th registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →6 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 1
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 43 across the 23 interventional studies, 0 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
3 of the studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT05980000Washington University School of MedicineRamucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | 2027-06-30 |
| NCT04852328Washington University School of MedicineThree Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin. The primary hypothesis is that olaparib, pembrolizumab and carboplatin will result in an overall response rate (ORR) higher than the historical ORR observed with pembrolizumab, platinum and 5-FU.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Normal bone marrow and organ function as defined below (specimens must be collected within 10 days prior to the start of study treatment):
or evidence of non-childbearing status for women of : negative urine or serum pregnancy test within 72 hours of Day 1 of study treatment:
*Postmenopausal is defined as:
Exclusion Criteria:
Female patients who are expecting to conceive or male patients who are expecting to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows: * Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles. * Pembrolizumab 200 mg intravenous (IV) Day 1. * Carboplatin AUC 5 IV on Day 1 for up to six cycles.
Drug: Olaparib · Drug: Pembrolizumab · Drug: Carboplatin · Procedure: Peripheral blood draw
Supplied by Merck \& Co.
Also known as: Lynparza
Supplied by Merck \& Co.
Also known as: Keytruda
Commercially available
Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
Objective Response Rate (ORR) as Assessed by RECIST v1.1
ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Duration of Response (DoR)
DoR is defined as time from date of first response (complete or partial) on CT scans through date of progression or last date of follow-up alive, whichever comes first. Complete response (CR) is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
Time frame: Through completion of follow-up (median length of follow-up 33.8 months, IQR=20.5-41.8 months)
Incidence of Adverse Events
Grade 1 to 2 adverse events with an incidence of ≥10% are shown. All grade 3 to 5 events are shown.
Time frame: Through 28 days after completion of treatment (median cycles (each cycle is 21 days) of treatment=10, IQR=3-26 cycles)
Correlation of Baseline Tumor HR and PTEN Gene Status With Objective Response Rate (ORR)
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor PD-L1 CPS Status With Objective Response Rate (ORR)
PD-L1 CPS status includes ≥20 or CPS 0-19. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor HPV (p16) Expression Status With Objective Response Rate (ORR)
Noted as HPV positive or HPV negative. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor HR and PTEN Gene Status With Median Progression Free Survival (PFS)
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor PD-L1 CPS Status With Median Progression-free Survival (PFS)
PD-L1 CPS status includes ≥20 or CPS 0-19. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor HPV (p16) Expression Status With Median Progression-free Survival (PFS)
Noted as HPV positive or HPV negative. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor HR and PTEN Gene Status With Median Overall Survival (OS)
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. OS is defined as the time from the date of first study treatment until death.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor PD-L1 CPS Status With Median Overall Survival (OS)
PD-L1 CPS status includes ≥20 or CPS 0-19. OS is defined as the time from the date of first study treatment until death.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Correlation of Baseline Tumor HPV (p16) Expression Status With Median Overall Survival (OS)
Noted as HPV positive or HPV negative. OS is defined as the time from the date of first study treatment until death.
Time frame: Through completion of follow-up (median length of follow-up 24.8 months, IQR=7.0-36.8 months)
Progression-free Survival (PFS)
PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
Time frame: Through completion of follow-up (estimated to be 3 years)
Overall Survival (OS)
OS is defined as the time from the date of first study treatment until death.
Time frame: Through completion of follow-up (estimated to be 3 years)
| Milestone | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Started | 30 |
| Completed | 4 |
| Not completed | 26 |
| Withdrew: Disease progression, relapse during active treatment | 18 |
| Withdrew: Death | 4 |
| Withdrew: Patient withdrawal or refusal after beginning protocol therapy | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Original biopsy showed scc further testing showed acc | 1 |
ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
| percentage of participants | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Objective Response Rate (ORR) as Assessed by RECIST v1.1 | 51.7 (35.2 to 68.0) |
DoR is defined as time from date of first response (complete or partial) on CT scans through date of progression or last date of follow-up alive, whichever comes first. Complete response (CR) is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Duration of Response (DoR) | 17.5 (6.8 to 37.6) |
Grade 1 to 2 adverse events with an incidence of ≥10% are shown. All grade 3 to 5 events are shown.
| Participants | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Grade 1/2 Abdominal pain | 3 |
| Grade 3/4/5 Acute kidney injury | 1 |
| Grade 1/2 Alanine aminotransferase increased | 5 |
| Grade 3/4/5 Alanine aminotransferase increased | 3 |
| Grade 1/2 Alkaline phosphatase increased | 8 |
| Grade 3/4/5 Anaphylaxis | 1 |
| Grade 1/2 Anemia | 18 |
| Grade 3/4/5 Anemia | 8 |
| Grade 1/2 Anorexia | 10 |
| Grade 3/4/5 Anorexia | 5 |
| Grade 1/2 Anxiety | 3 |
| Grade 1/2 Aspartate aminotransferase increased | 6 |
| Grade 3/4/5 Aspartate aminotransferase increased | 2 |
| Grade 3/4/5 Atrial flutter | 1 |
| Grade 3/4/5 Back pain | 1 |
| Grade 1/2 Blood bilirubin | 3 |
| Grade 1/2 Bone pain | 3 |
| Grade 1/2 Chills | 3 |
| Grade 3/4/5 Confusion | 1 |
| Grade 1/2 Constipation | 11 |
| Grade 1/2 Cough | 5 |
| Grade 1/2 Creatinine | 10 |
| Grade 3/4/5 Dental caries | 1 |
| Grade 1/2 Diarrhea | 8 |
| Grade 3/4/5 Diarrhea | 1 |
| Grade 1/2 Dizziness | 8 |
| Grade 1/2 Dry mouth | 3 |
| Grade 1/2 Dry skin | 10 |
| Grade 1/2 Dysarthria | 4 |
| Grade 1/2 Dysgeusia | 4 |
| Grade 1/2 Dysphagia | 9 |
| Grade 3/4/5 Dysphagia | 3 |
| Grade 1/2 Dyspnea | 8 |
| Grade 3/4/5 Dyspnea | 2 |
| Grade 1/2 Edema limbs | 7 |
| Grade 3/4/5 Esophageal fistula | 1 |
| Grade 1/2 Fatigue | 23 |
| Grade 3/4/5 Fatigue | 4 |
| Grade 3/4/5 Fall | 1 |
| Grade 3/4/5 Febrile neutropenia | 1 |
| Grade 3/4/5 Fracture | 1 |
| Grade 1/2 Fever | 3 |
| Grade 1/2 Headache | 3 |
| Grade 1/2 Hypercalcemia | 9 |
| Grade 1/2 Hyperkalemia | 10 |
| Grade 1/2 Hypertension | 8 |
| Grade 3/4/5 Hypertension | 1 |
| Grade 1/2 Hypoalbuminemia | 10 |
| Grade 1/2 Hypocalcemia | 6 |
| Grade 1/2 Hypoglycemia | 5 |
| Grade 1/2 Hypokalemia | 5 |
| Grade 3/4/5 Hypokalemia | 2 |
| Grade 1/2 Hyponatremia | 20 |
| Grade 1/2 Hypophosphatemia | 3 |
| Grade 1/2 Hypotension | 4 |
| Grade 3/4/5 Hypotension | 1 |
| Grade 1/2 Hypothyroidism | 5 |
| Grade 3/4/5 Hypoxia | 1 |
| Grade 3/4/5 Infusion related reaction | 1 |
| Grade 3/4/5 Laryngeal hemorrhage | 1 |
| Grade 3/4/5 Lung infection | 1 |
| Grade 3/4/5 Lymphedema | 1 |
| Grade 1/2 Lymphocyte count decreased | 5 |
| Grade 3/4/5 Lymphocyte count decreased | 16 |
| Grade 3/4/5 Mucosal infection | 1 |
| Grade 1/2 Mucositis oral | 6 |
| Grade 3/4/5 Mucositis oral | 1 |
| Grade 3/4/5 Myocardial infarction | 1 |
| Grade 1/2 Nasal congestion | 7 |
| Grade 1/2 Nausea | 13 |
| Grade 3/4/5 Nausea | 1 |
| Grade 1/2 Neck pain | 5 |
| Grade 1/2 Neutrophil count decreased | 5 |
| Grade 3/4/5 Neutrophil count decreased | 15 |
| Grade 3/4/5 Oral pain | 1 |
| Grade 3/4/5 Pericarditis | 1 |
| Grade 1/2 Peripheral sensory neuropathy | 4 |
| Grade 1/2 Platelet count decreased | 16 |
| Grade 3/4/5 Platelet count decreased | 5 |
| Grade 1/2 Productive cough | 3 |
| Grade 1/2 Rash maculo-papular | 4 |
| Grade 1/2 Sinus bradycardia | 4 |
| Grade 1/2 Sinus tachycardia | 4 |
| Grade 3/4/5 Skin infection | 1 |
| Grade 3/4/5 Soft tissue infection | 1 |
| Grade 3/4/5 Stoma site infection | 1 |
| Grade 3/4/5 Sudden death NOS | 1 |
| Grade 3/4/5 Syncope | 3 |
| Grade 3/4/5 Tooth infection | 1 |
| Grade 1/2 Upper respiratory infection | 5 |
| Grade 3/4/5 Urinary tract infection | 1 |
| Grade 1/2 Vomiting | 9 |
| Grade 1/2 Weight gain | 4 |
| Grade 1/2 Weight loss | 4 |
| Grade 3/4/5 Weight loss | 3 |
| Grade 1/2 White blood cell decreased | 13 |
| Grade 3/4/5 White blood cell decreased | 14 |
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
| Participants | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Altered with objective response of complete or partial response | 5 |
| Not altered with objective response of complete or partial response | 10 |
PD-L1 CPS status includes ≥20 or CPS 0-19. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
| Participants | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| PD-L1 CPS ≥20 with objective response of complete or partial response | 10 |
| PD-L1 CPS 0-19 with objective response of complete or partial response | 5 |
Noted as HPV positive or HPV negative. ORR is defined as the number of participants with complete response (CR) or partial response (PR) per RECIST v1.1. CR is defined as disappearance of target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. PR is defined as at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameters. Non-target lesions must be non-PD.
| Participants | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| HPV Positive with objective response of complete or partial response | 8 |
| HPV Negative with objective response of complete or partial response | 7 |
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Altered - median PFS (months) | NA (2.3 to NA) |
| Not Altered - median PFS (months) | 7.4 (2.6 to 14.5) |
PD-L1 CPS status includes ≥20 or CPS 0-19. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| PD-L1 CPS ≥20 with median PFS (months) | 10.8 (2.6 to 18.4) |
| PD-L1 CPS 0-19 with median PFS (months) | 7.4 (1.4 to 18.2) |
Noted as HPV positive or HPV negative. PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| HPV Positive with median PFS (months) | 11.3 (4.1 to 18.4) |
| HPV Negative with median PFS (months) | 5.1 (1.6 to NA) |
Noted as altered (defined as presence of an alteration in one or more HR genes or PTEN) or not altered. OS is defined as the time from the date of first study treatment until death.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Altered - median OS (months) | 14.7 (4.4 to NA) |
| Not Altered - median OS (months) | 24.5 (7.1 to 24.6) |
PD-L1 CPS status includes ≥20 or CPS 0-19. OS is defined as the time from the date of first study treatment until death.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| PD-L1 CPS ≥20 with median OS (months) | 24.5 (7.1 to NA) |
| PD-L1 CPS 0-19 with median OS (months) | 24.6 (4.1 to NA) |
Noted as HPV positive or HPV negative. OS is defined as the time from the date of first study treatment until death.
| months | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| HPV Positive with median OS (months) | 24.5 (6.9 to NA) |
| HPV Negative with median OS (months) | 12.7 (5.6 to NA) |
PFS is defined as time from study enrollment until the date of progression or death, whichever occurs first.
Results for this outcome have not been posted.
OS is defined as the time from the date of first study treatment until death.
Results for this outcome have not been posted.
Collected over Adverse events were evaluated from start of treatment to 30 days after completion of treatment. Median total time for adverse event collection was 8 months (full range 1 month-28 months). All cause mortality is followed from start of treatment to completion of follow up (up to 3 years).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib + Pembrolizumab + Carboplatin AUC | 19/30 (63.3%) | 12/30 (40%) | 30/30 (100%) |
| Event | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| AnemiaBlood and lymphatic system disorders | 1/30 |
| Atrial flutterCardiac disorders | 1/30 |
| Myocardial infarctionCardiac disorders | 1/30 |
| PericarditisCardiac disorders | 1/30 |
| DysphagiaGastrointestinal disorders | 1/30 |
| Esophageal fistulaGastrointestinal disorders | 1/30 |
| FatigueGeneral disorders | 1/30 |
| Sudden death NOSGeneral disorders | 1/30 |
| AnaphylaxisImmune system disorders | 1/30 |
| Lung infectionInfections and infestations | 1/30 |
| Event | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| White blood cell decreasedInvestigations | 27/30 |
| FatigueGeneral disorders | 26/30 |
| AnemiaBlood and lymphatic system disorders | 25/30 |
| Lymphocyte count decreasedInvestigations | 21/30 |
| Neutrophil count decreasedInvestigations | 20/30 |
| Platelet count decreasedInvestigations | 20/30 |
| HyponatremiaMetabolism and nutrition disorders | 20/30 |
| AnorexiaMetabolism and nutrition disorders | 15/30 |
| NauseaGastrointestinal disorders | 14/30 |
| ConstipationGastrointestinal disorders | 11/30 |
| Age, Continuous(years) | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Median | 66 (61 to 70) |
| Sex: Female, Male(Participants) | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Female | 6 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 30 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Olaparib + Pembrolizumab + Carboplatin AUC |
|---|---|
| United States | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Oct 2025, 50 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 50 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib
Squamous Cell Carcinoma of Head and Neck →
Washington University School of Medicine →